Nintedanib Found to Slow Progression of Fibrosing Interstitial Lung Disease

Bradley van Paridon
|
IPF
Interstitial pulmonary fibrosis (IPF). Computed tomography (CT) scan of lungs affected by IPF. The two dark structures are the lungs. The white space in the upper center is the heart. The left lung is the most severely affected, with diseased tissue appearing white. IPF is characterized by progressive thickening and stiffening of the lining of the air sacs in the lungs, causing breathlessness and pain. The cause is often unknown but in some cases the disease is thought to result from an autoimmune disorder. Without treatment IPF can lead to heart failure or bronchopneumonia. Treatment depends on the suspected underlying cause.
Researchers assessed the effect of nintedanib on changes in FVC% predicted in a 52-week study period.

The following article is a part of conference coverage from the American College of Rheumatology (ACR) Convergence 2021, being held virtually from November 3 to 10, 2021. The team at Rheumatology Advisor will be reporting on the latest news and research conducted by leading experts in rheumatology. Check back for more from the ACR Convergence 2021.
 

Nintedanib may slow the progression of interstitial lung disease (ILD) in patients with progressive fibrosing ILD other than idiopathic pulmonary fibrosis (IPF), according to study results presented at the American College of Rheumatology (ACR) Convergence 2021, held virtually from November 3 to 10, 2021.

The effect of nintedanib on categorical changes in forced vital capacity (FVC) % predicted over a period of 52 weeks was assessed among participants of the INBUILD trial.

Participants were diagnosed with diffuse fibrosing ILD of greater than 10% extent on high-resolution computed tomography (HRCT), FVC of at least 45% predicted, and carbon monoxide diffuse capacity (DLco) of at least 30% to less than 80% predicted. Study participants also met the criteria for progression of ILD within 24 months before screening.

The percentage of patients with categorical absolute increases or declines in FVC% predicted at week 52 were assessed in a post-hoc analyses.

Overall, 332 participants received nintedanib and 331 received placebo. Mean FVC at baseline was 68.7%±16.0% predicted and 69.3%±15.2% predicted in the nintedanib and placebo group, respectively. Absolute declines in FVC of greater than 5% to 10% or less predicted, of greater than 10% predicted, and of at least 5% predicted occurred in 19.7% of the treatment group and 22.7% of the placebo group, 12.3% of the treatment group and 25.1% of the placebo group, and 11.7% of the treatment group and 5.0% of the placebo group, respectively.

A subgroup analysis of 170 patients with autoimmune disease-related ILDs had similar findings.

Researchers concluded, “These results provide further support for the benefit of nintedanib on slowing the progression of ILD in subjects with progressive fibrosing ILD other than IPF.”

Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures. 

 

Visit Rheumatology Advisor’s conference section for complete coverage of ACR Convergence 2021.

 

Reference

Maher TM, Cerri S, Hallowell RW, et al. Effect of nintedanib on categorical changes in FVC in patients with progressive fibrosing ILDs: Further analyses of the INBUILD Trial. Presented at: ACR Convergence 2021; November 3 to 10, 2021. Abstract 0188.

  • Latest News Your top articles for Sunday

  • Haymarket Medical NetworkTop Picks

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More